Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Next Previous
X
Search
Trial Profile

Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Dasatinib; Dexamethasone; Methotrexate; Prednisone
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Feb 2025 added prednisone as it is given in Steroid Pre-Phase(improves symptoms and reduces chemotherapy-related side effects).
    • 25 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
    • 25 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top